1. Context {#sec111639}
==========

Dual anti-platelet therapy (DAPT), which was defined as the use of a P2Y12 receptor inhibitor (clopidogrel ([@A26904R1]), ticagrelor ([@A26904R2]) or prasugrel ([@A26904R3])) and aspirin, is an important clinical treatment strategy for patients after implantation of drug eluting stents (DES) ([@A26904R4], [@A26904R5]). Current clinical guidelines recommend 12 months of DAPT in patients after implantation of DES, who are not at a high risk of bleeding, and suggest that early discontinuation of DAPT may result in stent thrombosis ([@A26904R4]). However, considering the potential for TIMI major bleeding, the continuation of DAPT after DES implantation remains unclear ([@A26904R6]-[@A26904R9]). During the American Heart Association 2014 (AHA2014), many clinical trials (dual anti-platelet therapy (DAPT)) ([@A26904R10]), intracoronary stenting and antithrombotic regimen: safety and efficacy of 6 months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE) ([@A26904R11]) and is there a life for des after discontinuation of clopidogrel (ITALIC) ([@A26904R12])) about the optimal continuation time of DAPT after DES implantation were announced. However, the outcomes of these three clinical studies were different. Briefly, the outcomes from DAPT indicated that DAPT beyond one year after placement of DES could significantly reduce the risks of stent thrombosis, cerebrovascular events and major adverse cardiovascular, though with an increased risk of TIMI major bleeding. Conversely, patients assigned six months of DAPT had similar net clinical outcomes compared with patients assigned 12 months of DAPT after percutaneous coronary intervention (PCI) with a DES, according to new data from the ISAR-SAFE study. At the same time, the ITALIC trial showed that rates of bleeding and of thrombotic events were not significantly different for the six-month versus 24-month long DAPT after PCI with new generation DES in good aspirin responders. All in all, the optimal duration of DAPT after DES implantation remains uncertain until now. Here, a meta-analysis was performed to investigate the optimal duration, between ≤ 6 months and ≥ 12 months, for DAPT after implantation of DES.

2. Evidence Acquisition {#sec111644}
=======================

A meta-analysis of available published researches about intervention of DAPT after DES implantation was performed. During December 2014, a literature search was conducted at the department of cardiology, the first college of clinical medical sciences, Institute of cardiovascular diseases, China, Three Gorges university. Articles, which had been published before December 2014 were preselected.

2.1. Literature Search Strategy {#sec111640}
-------------------------------

To identify all prospective randomized controlled trials (RCTs) of DAPT after DES implantation, we systematically searched the literature through the Pub-med, Scopus, Cochrane and clinicaltrials.gov databases. Searches of the above database included the following phrases, "dual anti-platelet therapy" and "Myocardial Infarction (MI)" and "drug-eluting stents (DES)." The search was filtered to show only English articles and was limited to clinical trials. The steps of the literature search process are summarized in [Figure 1](#fig21289){ref-type="fig"}.

![Flow Diagram of the Study Selection Process in the Meta-Analysis](ircmj-17-07-26904-i001){#fig21289}

2.2. Criterions of Inclusion and Exclusion {#sec111641}
------------------------------------------

The inclusion criteria were as follows: 1) randomized clinical trial, 2) patients with implantation of DES older than 18 years 3) DAPT ≤ 6 months OR ≥ 12 months, 4) DAPT used were aspirin and clopidogrel, 5) English language studies. We excluded trails that did not report any of the outcomes mentioned above and articles without the data available.

2.3. Data Collection Process {#sec111642}
----------------------------

The identification of titles and abstracts and extracting of data were independently screened by two reviewers (FZ and YC). The corresponding author (YJ) was responsible for the potential of disagreement and discordance between the two reviewers. Quality assessments were evaluated with the Jadad quality scale (a numerical score between zero and seven, with zero being the weakest and seven being the strongest), including the following: 1) double blinding, 2) allocation concealment, 3) random sequence generation and 4) description of withdrawals and drop-outs.

2.4. Statistical Analysis {#sec111643}
-------------------------

All statistical analyses were performed using the RevMan 5.0 software, provided by the Cochrane Collaboration. The effect measure of odds ratio (OR) with 95% Confidence Interval (CI) and the statistical method of random effects were used. Heterogeneity was assessed using I^2^ statistics and the statistical significance was set at 0.05.

3. Results {#sec111649}
==========

3.1. Included Clinical Trials {#sec111645}
-----------------------------

There were 223 relevant reports identified by the search; nine full text articles were retrieved for detailed evaluation. In total, five RCTs enrolling 9,979 participants (4,993 patients were with shorter duration of DAPT and 4,986 patients with a longer treatment) satisfying the inclusion criteria were finally analyzed. [Figure 1](#fig21289){ref-type="fig"} shows the flow diagram of the study selection process in the meta-analysis. According to the Jadad quality scale, all included trials were of general quality (the score was five), as indicated by [Table 1](#tbl28733){ref-type="table"}. All five RCTs were published between 2012 and 2014 and all the five RCTs were open-label yet not double blind, which may bias the results.

###### Summary of Quality Evaluation by the Jadad Scale for Clinical Trials of Dual Anti-Platelet Therapy After Drug Eluting Stents Implantation

  Trials                                    Random Sequence Generation   Allocation Concealment   Double Blinding   Description of Withdrawals and Drop-Out   Score
  ----------------------------------------- ---------------------------- ------------------------ ----------------- ----------------------------------------- -------
  **Excellent (** [@A26904R13] **) 2012**   2                            1                        1                 1                                         5
  **Prodigy (** [@A26904R14] **) 2012**     2                            1                        1                 1                                         5
  **Reset (** [@A26904R15] **) 2012**       2                            1                        1                 1                                         5
  **Optimize (** [@A26904R16] **) 2013**    2                            1                        1                 1                                         5
  **Italic (** [@A26904R12] **) 2014**      2                            1                        1                 1                                         5

3.2. Characteristics of the Included Clinical Trials {#sec111646}
----------------------------------------------------

The baseline characteristics of patients in both ≤ 6 months and ≥ 12 months groups were similar (characteristics of the clinical trials are shown in [Table 2](#tbl28734){ref-type="table"}). Females were under-represented compared to males in all trials (about 30%). Participants in all five RCTs had a mean age of 63 years and there were about 49% acute coronary syndromes (ACS) patients in this meta-analysis. The mean duration of the shorter duration group was 4.8 months while for the longer duration group this was 17 months.

###### Characteristics of the Included Clinical Trials ^[a](#fn28223){ref-type="table-fn"},[b](#fn28224){ref-type="table-fn"}^

  Clinical Trials                                       Excellent ([@A26904R13]) 2012                                            Prodigy ([@A26904R14]) 2012                                              Reset ([@A26904R15]) 2012                                                Optimize ([@A26904R16]) 2013                                             Italic ([@A26904R12]) 2014                                                                                                                                
  ----------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------ ------------------- -------------------- ------------------- ------------------- ------------------
  **Group**                                             Shorter (n = 722)                                                        Longer (n = 721)                                                         Shorter (n = 737)                                                        Longer (n = 741)                                                         Shorter (n = 1059)                                                       Longer (n = 1058)   Shorter (n = 1563)   Longer (n = 1556)   Shorter (n = 910)   Longer (n = 912)
  **Identifier NO.**                                    NCT00698607                                                              NCT00611286                                                              NCT01145079                                                              NCT01113372                                                              NCT 01476020                                                                                                                                              
  **Female** ^**[b](#fn28224){ref-type="table-fn"}**^   34.9                                                                     36.1                                                                     24.0                                                                     22.6                                                                     35.6                                                                     37.1                36.5                 36.9                19.2                20.8
  **Age, y**                                            63.0                                                                     62.4                                                                     67.9                                                                     67.8                                                                     62.4                                                                     62.4                61.3                 61.9                61.7                61.5
  **ACS** ^**[b](#fn28224){ref-type="table-fn"}**^      51.1                                                                     52.0                                                                     73.5                                                                     73.3                                                                     55.5                                                                     53.7                31.6                 32.3                43.4                43.5
  **Sent type**                                         Sirolimus Everolimus                                                     Paclitaxel Everolimus Zotarolimus                                        Sirolimus Everolimus Zotarolimus                                         Zotarolimus                                                              Xience V                                                                                                                                                  
  **Duration of DAPT, months**                          6                                                                        12                                                                       6                                                                        24                                                                       3                                                                        12                  3                    12                  6                   24
  **Intervention**                                      12 month aspirin or clopidogrel versus 3 month aspirin and clopidogrel   24 month aspirin or clopidogrel versus 6 month aspirin and clopidogrel   12 month aspirin or clopidogrel versus 3 month aspirin and clopidogrel   12 month aspirin or clopidogrel versus 3 month aspirin and clopidogrel   24 month aspirin or clopidogrel versus 6 month aspirin and clopidogrel                                                                                    
  **Primary end point**                                 Composite of all cause death, MI, stroke, or major bleeding              Composite of all cause death, MI, stroke, or major bleeding              Composite of all cause death, MI, stroke, or major bleeding              Composite of all cause death, MI, stroke, or major bleeding              Composite of all cause death, MI, stroke, or major bleeding                                                                                               

^a^ Abbreviations: ACS, acute coronary syndromes; DAPT, Dual Anti-Platelet Therapy; MI, myocardial infarction.

^b^ Values are presented as %.

3.3. The Results of Data Analysis {#sec111647}
---------------------------------

All the five RCTs had a good homogeneity, thus this meta-analysis used a fixed effects model. All causes of death, MI, cardiac death, cerebrovascular accident, stent thrombosis and major bleeding were assessed in this meta-analysis. Longer duration of therapy (≥ 12 months) did not reduce the risk of mortality, including, all causes of death, cardiac death, cerebrovascular accidents, myocardial infarction and stent thrombosis (pooled OR 1.03, 95% CI 0.80 - 1.32, P = 0.85, I^2^ = 0%, [Figure 2](#fig21290){ref-type="fig"} A; pooled OR 0.91, 95% CI 0.64 - 1.29, P = 0.60, I^2^ = 0%, [Figure 2](#fig21290){ref-type="fig"} B; pooled OR 0.84, 95% CI 0.50 - 1.42, P = 0.51, I^2^ = 0% , [Figure 2](#fig21290){ref-type="fig"} C; pooled OR 1.17, 95% CI 0.87 - 1.58, P = 0.29, I^2^ = 0%, [Figure 2](#fig21290){ref-type="fig"} D; pooled OR 1.36, 95% CI 0.81 - 2.29, P = 0.24, I^2^ = 0%, [Figure 2](#fig21290){ref-type="fig"} E). Longer duration (≥ 12 months) increased the risk of TIMI major bleeding (pooled OR 0.50, 95% CI 0.29 - 0.85, P = 0.01, I^2^ = 0%; [Figure 3](#fig21291){ref-type="fig"}). The total events of primary end points of DAPT after DES implantation are summarized in [Table 3](#tbl28735){ref-type="table"}.

![Effect of Long and Short Duration of Therapy on the Risk of Death Caused by Cardiac Arrest, Cerebrovascular Accidents, Myocardial Infarction, Stent Thrombosis and Other Causes of Death\
Pooled OR 1.03, 95% CI 0.80 - 1.32, P = 0.85, I^2^ = 0%, A; pooled OR 0.91, 95% CI 0.64 - 1.29, P = 0.60, I^2^ = 0%, B; pooled OR 0.84, 95% CI 0.50 - 1.42, P = 0.51, I^2^ = 0%, C; pooled OR 1.17, 95% CI 0.87 - 1.58, P = 0.29, I^2^ = 0%, D; pooled OR 1.36, 95% CI 0.81 - 2.29, P = 0.24, I^2^ = 0%, E.](ircmj-17-07-26904-i002){#fig21290}

![Longer Duration (≥ 12 Months) Could Increase the Risk of thrombolysis in myocardial infarction (TIMI) Major Bleeding\
Pooled OR 0.50, 95% CI 0.29 - 0.85, P = 0.01, I^2^ = 0%.](ircmj-17-07-26904-i003){#fig21291}

###### Summary of Primary End Points of Clinical Trials of Dual Anti-Platelet Therapy After Drug Eluting Stents Implantation

  Primary end Points            Shorter, ≤ 6 mo, (n = 4993)   Longer, ≥ 12 mo, (n = 4986)   OR                  P Value
  ----------------------------- ----------------------------- ----------------------------- ------------------- ---------
  **All causes of mortality**   125                           122                           1.03 (0.80, 1.32)   0.85
  **Cardiac death**             63                            69                            0.91 (0.64, 1.29)   0.60
  **Cerebrovascular**           26                            31                            0.84 (0.50, 1.42)   0.51
  **MI**                        96                            82                            1.17 (0.87, 1.58)   0.29
  **Stent thrombosis**          34                            25                            1.36 (0.81, 2.29)   0.24
  **TIMI major bleeding**       20                            40                            0.50 (0.29, 0.85)   0.01

3.4. Evaluation for Publication Bias {#sec111648}
------------------------------------

Considering all the five RCTs, the funnel plot of all causes of mortality was symmetrical ([Figure 4](#fig21292){ref-type="fig"}), which indicates that publication bias is low.

![The Funnel Plot for All Causes of Mortality](ircmj-17-07-26904-i004){#fig21292}

4. Conclusions {#sec111650}
==============

Current clinical guidelines recommend 12 months of DAPT following implantation of DES ([@A26904R4], [@A26904R9], [@A26904R17], [@A26904R18]). However, the optimal duration of DAPT after implantation of DES remains undetermined. Recently, some RCTs have compared the different outcomes between shorter and longer duration of DAPT after DES implantation ([@A26904R10]-[@A26904R12]). However, the outcomes are still the subject of ongoing debate ([@A26904R19]).

During the AHA2014, many clinical trials (DAPT, ISAR-SAFE and ITALIC) about the optimal duration of DAPT after DES implantation were announced. However, the outcomes from these three clinical studies were different. Briefly, the outcomes from DAPT indicated that DAPT beyond one year after placement of a DES significantly reduced the risks of cerebrovascular events, stent thrombosis and major adverse cardiovascular, though with an increased risk of TIMI major bleeding. Conversely, patients assigned to six months of DAPT had similar net clinical outcomes compared with patients assigned to 12 months of DAPT after PCI with a DES, according to new data from the ISAR-SAFE study. At the same time, the ITALIC trial showed that rates of bleeding and of thrombotic events were not significantly different for the 6- versus 24-month DAPT program after PCI with new generation DES in good aspirin responders.

Here, a meta-analysis was performed to investigate the different outcomes between ≤ 6 months and ≥ 12 months DAPT after DES. Our findings were in agreement with previous publications ([@A26904R7]-[@A26904R9]). However, it also had some differences with previous reports. The biggest difference was that we included the latest clinical study (ITALIC). Similarly, the latest published meta-analysis, ([@A26904R6]) carried out by Elmariah et al. ([@A26904R6]) identified 14 eligible trials (but without ITALIC) that randomly assigned 69644 participants to different durations of DAPT. The outcomes indicated that compared with aspirin alone or short duration of DAPT, continued treatment was not associated with a difference in all causes of mortality, cardiovascular and non-cardiovascular mortality. Thus, compared to the meta-analysis of Elmariah et al. ([@A26904R6]) our meta-analysis only analyzed the shorter (≤ 6 months) and longer (≥ 12 months) duration of DAPT without comparing aspirin alone. However, the outcomes of our meta-analysis were also in agreement with this meta-analysis. In other words, the findings of our meta-analysis suggested that to stabilize coronary atherosclerotic heart disease (CAD) patients, the duration of ≤ 6 months and ≥ 12 months may be equally effective yet the longer duration was associated with increased risk of bleeding.

Of course, this meta-analysis also had some limitations; there was no patient level data and the five RCIs were not double blinded. Besides, different stent types were used in these five different studies ([Table 2](#tbl28734){ref-type="table"}), which may also affect the outcome. Third, the only used P2Y12 receptor inhibitor in this meta-analysis was clopidogrel. The other inhibitors, ticagrelor and prasugrel, were not included in the analysis. Last but not least, the five studies had a low event rate, and ITALIC was prematurely terminated due to problems with recruitment, which would influence the quality of the clinical trials.

The optimal duration for DAPT after the implantation of DES is still undetermined. In clinical practice, the treatment plan of DAPT on different patients should be based on the individual's specific circumstances. For example, patients with a history or other risk factors for bleeding may be suitable for shortened period of DAPT. While, patients with a higher risk of thrombotic events (for example, with a variety of ischemic disease or multiple risk factors) should be on extended treatment. This meta-analysis was only an investigation in this area and the results may be more appropriately applied to stable CAD patients.
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